SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4